Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 20 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Barrett's esophagus and H pylori as prognosis for GERD

H pylori infection has a positive influence on healing in patients with erosive reflux disease and coexistent Barrett's esophagus but no influence on those without Barrett's esophagus, finds the latest issue of Gut.

News image

fiogf49gjkf04

Adequacy of acid suppression is a critical factor influencing healing in gastro-esophageal reflux disease (GERD).

The European prospective study ProGERD was set up to determine the endoscopic and symptomatic progression of GERD over 5 years under routine care, after initial acid suppression with esomeprazole.

Dr Malfertheiner and colleagues report on factors influencing endoscopic healing and symptom resolution during the acute treatment phase.

The research team obtained biopsies from the esophagus of patients with symptoms suggestive of GERD who underwent endoscopy.

The team used the information obatined from the biopsied for diagnosis of abnormalities, including Barrett’s esophagus.

Age, sex, and body mass index appear to have no significant impact on healing
Gut

The researchers included data from 6215 patients in the ‘intention to treat’ analysis.

The investigators reported that 3245 patients were diagnosed as having erosive reflux disease and 2970 non-erosive reflux disease.

Patient with erosive reflux disease patients were treated with esomeprazole 40 mg for 4 to 8 weeks for endoscopic healing.

The team reported that patients with non-erosive reflux disease received 20 mg esomeprazole for 2 to 4 weeks for resolution of heartburn symptoms.

The team found that endoscopic healing occurred overall in 88% of erosive reflux disease patients.

Endoscopic healing was significantly lower at 77% in those with more severe oesophagitis and at 73% in those with Barrett’s esophagus.

The researchers noted that endoscopic healing was particularly lower at 70% in Helicobacter pylori negative patients with Barrett’s esophagus.

The investigators observed that age, sex, and body mass index appeared to have no significant impact on healing.

Complete heartburn resolution was reported by 70% of erosive reflux disease patients and by 65% of non-erosive reflux disease patients at the last visit.

In addition, the team found that only H pylori infection had a significant influence on complete heartburn resolution in the non-erosive reflux disease group.

Dr Malfertheiner’s team concludes, “The presence of Barrett’s mucosa, as well as severe mucosal damage, exerts a negative impact on healing.”

H pylori infection had a positive influence on healing in patients with erosive reflux disease and coexistent Barrett’s esophagus but no influence on those without Barrett’s esophagus.”

Gut 2005: 54: 746-751
16 May 2005

Go to top of page Email this page Email this page to a colleague

 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 20 February 2018 
Complications and surveillance colonoscopies
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis
 26 January 2018 
Optimizing selection of biologics in IBD
 26 January 2018 
Nutritional risk and laparoscopic-assisted gastrectomy outcomes
 25 January 2018 
Patient-reported outcome measure for functional dyspepsia
 25 January 2018 
Predicting intra-abdominal infections after colorectal surgery
 25 January 2018 
Predictors of gastric cancer risk
 24 January 2018 
Risk factors underlying previously undiagnosed cirrhosis
 24 January 2018 
Ethnicity influences phenotype in IBD
 24 January 2018 
Bariatric surgery vs medical obesity treatment
 23 January 2018 
Atrophic gastritis after H. pylori eradication

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us